Changes in the contents of four active diterpenoids at different growth stages in Andrographis paniculata (Burm.f.) Nees (Chuanxinlian). Pholphana N, Rangkadilok N, Saehun J, Ritruechai S, Satayavivad J Chinese Medicine 2013; 8: 1-12.

15 Jan 2013
0
0

Changes in the contents of four active diterpenoids at different growth stages in Andrographis paniculata (Burm.f.) Nees (Chuanxinlian).
Pholphana N, Rangkadilok N, Saehun J, Ritruechai S, Satayavivad J
Chinese Medicine 2013; 8: 1-12.

Tags

Share this

Related Posts

An engineered cell line lacking OGG1 and MUTYH glycosylases implicates the accumulation of genomic 8-oxoguanine as the basis for paraquat mutagenicity. Tajai, P., Fedeles, B. I., Suriyo, T., Navasumrit, P., Kanitwithayanun, J., Essigmann, J. M., &Satayavivad, J. (2018). Free Radical Biology and Medicine, 116, 64-72.
28 Dec 2018
0

An engineered cell line lacking OGG1 and MUTYH glycosylases implicates the accumulation of genomic 8-oxoguanine as the basis for paraquat mutagenicity. Tajai, P., Fedeles, B. I., Suriyo, T., Navasumrit, P., Kanitwithayanun, J., Essigmann, J. M., &Satayavivad, J. (2018). Free Radical Biology and Medicine, 116, 64-72.

An engineered cell line lacking OGG1 and MUTYH glycosylases implicates the accumulation of genomic 8-oxoguanine as the basis for paraquat mutagenicity. Tajai, P., Fedeles, B. I., Suriyo, T., Navasumrit, P., Kanitwithayanun, J., Essigmann, J. M., &Satayavivad, J. (2018). Free Radical Biology and Medicine, 116, 64-72.
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
New
20 Sep 2023
0
New

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More